Literature DB >> 11846317

PEA I and PEA II based implantable haemodynamic monitor: pre clinical studies in sheep.

G Plicchi1, E Marcelli, M Parlapiano, T Bombardini.   

Abstract

AIMS: The aims of this study were first, to demonstrate that Peak Endocardial Acceleration during isovolumic systole (PEA I) is related to positive peak LVdP/dt, while Peak Endocardial Acceleration during isovolumic relaxation time (PEA II) is related to aortic diastolic pressure (ADP) and to negative peak LVdP/dt; and second, to test if the simultaneous recording of PEA I and PEA II offers a new chance to monitor indexes of LV systolic and diastolic function.
METHODS: An implantable haemodynamic monitor, based on PEA I and PEA II measurements via a microaccelerometer sensor located in the tip of a pacing lead, screwed into the right ventricle, was tested in nine sheep at baseline and during acute haemodynamic interventions: nitrate (0.1 mg/ kg), metaraminol (0.15 mg/kg), dobutamine (5 microg/kg) infusion. ADP, positive and negative peak LVdP/dt were simultaneously recorded by an aortic and left ventricular Millar catheter.
RESULTS: PEA I changes were significantly related to positive peak LVdP/dt changes during dobutamine induced inotropic changes (r = 0.83, P < 0.001). PEA II changes were significantly related to both ADP (r = 0.91, P < 0.001) and negative peak LVdP/dt changes (r = 0.92, P < 0.001) during nitrate induced hypotension and metaraminol induced hypertension.
CONCLUSION: The simultaneous recording of PEA I and PEA II with an implantable system offers a new chance to monitor indexes of LV systolic and diastolic function.

Entities:  

Mesh:

Year:  2002        PMID: 11846317     DOI: 10.1053/eupc.2001.0204

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  8 in total

1.  Analysis of endocardial acceleration during intraoperative optimization of cardiac resynchronization therapy.

Authors:  Alfredo I Hernandez; Filippo Ziglio; Amel Amblard; Lotfi Senhadji; Christophe Leclercq
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2013

Review 2.  Are electronic cardiac devices still evolving?

Authors:  G Carrault; P Mabo
Journal:  Yearb Med Inform       Date:  2014-08-15

Review 3.  Implantable diagnostic monitoring devices for evaluation of syncope, and tachy- and brady-arrhythmias.

Authors:  David G Benditt; Cengiz Ermis; Scott Pham; Laura Hiltner; Amy Vrudney; Keith G Lurie; Scott Sakaguchi
Journal:  J Interv Card Electrophysiol       Date:  2003-10       Impact factor: 1.900

4.  Usefulness of hemodynamic sensors for physiologic cardiac pacing in heart failure patients.

Authors:  Eraldo Occhetta; Miriam Bortnik; Paolo Marino
Journal:  Cardiol Res Pract       Date:  2011-03-15       Impact factor: 1.866

Review 5.  Optimal management of the critically ill: anaesthesia, monitoring, data capture, and point-of-care technological practices in ovine models of critical care.

Authors:  Saul Chemonges; Kiran Shekar; John-Paul Tung; Kimble R Dunster; Sara Diab; David Platts; Ryan P Watts; Shaun D Gregory; Samuel Foley; Gabriela Simonova; Charles McDonald; Rylan Hayes; Judith Bellpart; Daniel Timms; Michelle Chew; Yoke L Fung; Michael Toon; Marc O Maybauer; John F Fraser
Journal:  Biomed Res Int       Date:  2014-03-25       Impact factor: 3.411

Review 6.  Ambulatory Heart Failure Monitoring: A Systemic Review.

Authors:  Muhammad A Mangi; Hiba Rehman; Muhammad Rafique; Michael Illovsky
Journal:  Cureus       Date:  2017-04-18

7.  Validation of a peak endocardial acceleration-based algorithm to optimize cardiac resynchronization: early clinical results.

Authors:  Peter Paul Delnoy; Emanuela Marcelli; Henk Oudeluttikhuis; Deborah Nicastia; Fabrizio Renesto; Laura Cercenelli; Gianni Plicchi
Journal:  Europace       Date:  2008-05-19       Impact factor: 5.214

8.  Proteogenomics of selective susceptibility to endotoxin using circulating acute phase biomarkers and bioassay development in sheep: a review.

Authors:  Saul Chemonges; John-Paul Tung; John F Fraser
Journal:  Proteome Sci       Date:  2014-03-01       Impact factor: 2.480

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.